Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track GNLX with free AI briefings, catalyst countdowns, and dilution alerts.

GNLX · Genelux Corporation

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

On the Downside Radar: financing pressure. About 9.0 months of cash at its recent burn rate (Jun 30, 2026 balance sheet), an at-the-market (ATM) program filed Mar 19, 2026, and no offering in the last 90 days. Of biotech stocks in this setup with 6 to 12 months of cash, 35% sold new shares within three months and 67% were lower 60 trading days later (median -12%). How we know
$18.7M Cash on Hand
9mo Cash Runway
9.9% Short Interest
$18.83 Analyst Target (6)
Follow GNLX by email Get an email when GNLX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about GNLX, unsubscribe in one click. Privacy

📣 What GNLX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Olvimulogene Nanivacirepvec Platinum-resistant Ovarian Cancer Phase 3 · NCT05281471 Recruiting
Platinum chemotherapy: carboplatin (preferred)… Platinum-resistant Ovarian Cancer Phase 3 · NCT05281471 Recruiting
Non-platinum chemotherapy: paclitaxel or… Advanced Non-squamous Non-small-cell Lung Cancer Phase 2 · NCT06463665 Recruiting
Platinum SCLC, Extensive Stage Phase 1/2 · NCT07136285 Recruiting
Platinum-doublet with or without bevacizumab Ovarian Cancer Phase 1/2 · NCT02759588 Completed

Also used in these trials (approved or third-party drugs, not GNLX's own candidates): Bevacizumab, Docetaxel Anhydrous, Etoposide.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

GNLX holds $18.7M in cash and short-term investments (as of Jun 30, 2026) and burns about $6.3M/quarter from operations, an estimated runway of 9 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 94 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when GNLX files for a raise →

👥 Who Owns GNLX

Insiders 7% Other 5%+ holders 5.9% Institutions (85 holders) 31.5% Public and other holders 55.6%
HolderTypeShares% of sharesAs of
Aladar Szalay 5%+ holder (13G) 2,834,465 5.90% 2026-09-30
Woodward Diversified Capital, LLC Institution (13F) 2,262,108 4.71% 2026-06-30
Vanguard Capital Management LLC Institution (13F) 1,677,724 3.49% 2026-06-30
Thomas Zindrick
President and CEO · +1.83M options
Insider 1,423,338 2.96% 2026-11-03
Bleichroeder LP Institution (13F) 1,380,666 2.87% 2026-06-30
John Thomas
Director · +60,142 options
Insider 501,193 1.04% 2026-06-16
Blackrock Inc. Institution (13F) 439,602 0.91% 2026-06-30
Geode Capital Management, LLC Institution (13F) 439,213 0.91% 2026-06-30
CM Management, LLC Institution (13F) 400,000 0.83% 2026-06-30
Bank of America Corporation Institution (13F) 328,803 0.68% 2026-06-30
Joseph Cappello
Chief Technical Officer · +174,999 options
Insider 317,812 0.66% 2026-11-03
Matthew Pulisic
Chief Financial Officer
Insider 278,906 0.58% 2026-06-16

Share count 48,064,184 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-08-31
filed 2026-09-02
Zindrick Thomas
Sale (S) 34,463 $2.67 1,226,427
2026-08-31
filed 2026-09-02
Yu Yong
Sale (S) 9,683 $2.75 258,688
2026-08-31
filed 2026-09-02
Cappello Joseph
Sale (S) 10,257 $2.74 318,480
2026-08-04
filed 2026-08-04
Yu Yong
Sale (S) 653 $2.94 268,371
2026-08-04
filed 2026-08-04
Cappello Joseph
Sale (S) 653 $2.95 328,737

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full GNLX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GNLX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.